Loading
SCHOTT Pharma AG & Co. KGaA Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 13 Feb 2026.
SCHOTT Pharma AG & Co. KGaA: what insiders have been doing
Every trade that managers of SCHOTT Pharma AG & Co. KGaA disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Mainz. The last twelve months, up to 18 October 2026, brought 3 filings signed by 3 insiders.
Only purchases show up on the open market, 3 purchases in all worth €206k, filed by 3 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €110k, bought by Derr, Dr. Torsten and made public on 12 February 2026. The buyers include 2 senior executives and 1 board member.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 246 days ago, on 13 February 2026. Between a trade and the moment it shows up on BaFin, the median delay is 1 day. The regulation allows three business days to notify a trade (MAR article 19).
Across the 287 companies tracked on its exchange, the median is 5 filings; at 3 filings, this issuer sits below that mark. The full history, which starts in 2025, counts 3 purchases against no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by BaFin and describes the past, not future prices; it is not investment advice.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€205,523
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleReinhard Mayer3 buys
Dr. Torsten Derr1 buy
Since the insiders bought
- +63.4%Entry €15.02 · Close 16 Oct 2026 €24.55
- +63.4%Entry €15.02 · Close 16 Oct 2026 €24.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate SCHOTT Pharma AG & Co. KGaA Buy (bullish), based on 12 analysts. Average price target: €20.48.
Fundamental score
Ranked 6,899 of 24,148 companies
62.3
score / 100
Value52
Quality73
FCF yld1.1%
Earn yld4.5%
EV/EBITDA11.7x
ROE15%
Gross mgn34%
Net mgn15%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
€21.80
Analyst consensus
12 analystsBuy
€13.00Target €20.48(-6%)€26.50
Income statement
Revenue€986.2M
Gross profit€332.5M34% margin
EBITDA€287.2M29% margin
Net income€146.5M13.4% margin
Valuation
PER (trailing)22.9x
PER (forward)20.4x
P/Book3.3x
Beta0.95
Balance sheet & cash
Market cap€3.3B
Total debt€83.0M
Free Cash Flow€35.2M
Debt / Equity23%
Profitability & ownership
ROE14.7%
ROA6.4%
% insiders77.0%
% institutions19.3%
Last declaration on 13 February 2026
Declarations3 total
3,350.198 shares@ €15.1253.1% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325-aeae05223ebe
Canonical exit: 13 May 2026 (T+90)
6,998.67 shares@ €15.73100.0% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325-b0487163ba29
Canonical exit: 12 May 2026 (T+90)
2,999.236 shares@ €14.9346.9% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325
Canonical exit: 18 Mar 2026 (T+90)
3 of 3 declarations
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA is a leading provider of drug containment solutions and delivery systems for injectable medicines. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, the company holds a strong position in the pharmaceutical packaging value chain through a portfolio that includes prefillable syringes, cartridges, vials, ampoules, and related analytical, development, fill-and-finish, and regulatory services. SCHOTT Pharma describes itself as an end-to-end partner for pharmaceutical companies, biotech firms, and CDMOs, supplying both Type I borosilicate glass and advanced pharmaceutical polymer solutions. ([schott-pharma.com](https://www.schott-pharma.com/?utm_source=openai))
The company’s heritage is rooted in the broader SCHOTT group, which traces back more than 130 years to Otto Schott and his breakthroughs in specialty glass. SCHOTT Pharma was established as a standalone business in 2022 to accelerate growth and strengthen its capital-market profile. Its corporate headquarters are in Mainz, Germany, and its industrial footprint is global, with 16 GMP-compliant manufacturing sites across Europe, North America, South America, and Asia. The company states that it employs around 4,700 people worldwide, underscoring a sizeable international platform despite its specialist focus. ([schott-pharma.com](https://www.schott-pharma.com/en/about-us?utm_source=openai))
Read moreShow less
From a competitive standpoint, SCHOTT Pharma benefits from a reputation for technical leadership in a market supported by long-term structural demand drivers: biologics, GLP-1 therapies, ADCs, and increasing use of cold-chain and home-administration formats. The company highlights a customer base of more than 1,700 clients, including many of the world’s leading pharmaceutical manufacturers, and emphasizes one of the broadest product ranges in the market. A central strategic pillar is the expansion of higher-margin “high-value solutions,” which has consistently increased its contribution to revenue and profitability. ([schott-pharma.com](https://www.schott-pharma.com/en/news-and-media/media-releases/2022/schott-establishes-stand-alone-company-for-pharma-business-to-promote-further-growth?utm_source=openai))
Recent developments reinforce the investment case as a growth-and-margin story. In fiscal 2025, SCHOTT Pharma reported solid quarterly performance and later delivered full-year revenue of EUR 986.2 million with an EBITDA margin of 28.4%, while the share of high-value solutions rose to 57%. Management also guided for fiscal 2026 revenue growth of 2% to 5% at constant currencies and an EBITDA margin of around 27%. Governance updates in 2025 included the extension of CEO Andreas Reisse’s contract and the appointment of Reinhard Mayer as CFO, suggesting strategic continuity rather than disruption. ([schott-pharma.com](https://www.schott-pharma.com/en-gr/home/news-and-media/media-releases/2025/schott-pharma-delivers-on-full-year-revenue-and-profitability-targets?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
